Delfina Secures $17M to Revolutionize Maternal Care with Cutting-Edge Predictive AI Technology
Delfina has successfully raised $17 million in a recent Series A funding round, highlighting significant investor confidence in its innovative approach to improving maternal healthcare through cutting-edge AI technology. This funding, spearheaded by US Venture Partners (USVP), also saw contributions from various reputable investors, including ARTIS Ventures, Mayo Clinic, and Chelsea Clinton’s Metrodora Ventures.
Transforming Maternal Healthcare with AI
Based in San Francisco, Delfina utilizes AI-powered predictive analytics to tackle the urgent maternal health crisis in the United States. Their platform is designed to integrate seamlessly with primary prenatal care teams, enabling the creation of personalized, data-driven healthcare plans. This approach aims to significantly reduce maternal mortality rates and improve outcomes for both mothers and infants.
The Maternal Health Crisis in the U.S.
The current maternal mortality rate in the U.S. exceeds that of other high-income countries by more than double. This crisis disproportionately affects Black women, whose mortality rates are nearly three times higher than those of white women. Delfina’s technology addresses these disparities by focusing on equitable access to quality care and tackling unmet social determinants of health.
Funding Utilization and Future Plans
The recently acquired funding will facilitate Delfina’s national expansion, allowing the company to enhance its predictive technology and intervention strategies. This expansion will help reach a broader patient base, particularly in underserved communities. Delfina aims to establish itself as a leading technology partner for healthcare providers, payors, and families, with a mission centered on improving maternal health outcomes and fostering systemic change.
Statements from Leadership
Delfina’s CEO, Dr. Senan Ebrahim, expressed gratitude for the support received from investors and partners, stating, “This funding marks a significant milestone in Delfina’s journey to address the national maternal health crisis. With this capital, we will accelerate our services to diverse populations and scale our impact across the nation.”
USVP general partner, Dafina Toncheva, emphasized the importance of Delfina’s technology, stating, “Delfina’s care system utilizes advanced machine learning technology to create measurable impacts in our healthcare system, particularly for underserved Medicaid patients. We are excited to support Delfina in revolutionizing pregnancy care for all families.”
For more information about Delfina and its mission, visit their official website or check out their latest updates on Twitter.
